TXG 10x Genomics, Inc.
Company Analysis
Latest News
🟢 10x Genomics is trading 4.6% up in pre-market after Canaccord and Piper Sandler raised targets
10x Genomics is trading 4.6% up at $61.15 after analysts raised their price targets following the company’s second-quarter results. - Canaccord raised its...
10x Genomics Rides an Atera-Fueled Rally Past $57 — But Can a 40-Unit Shipment Cap Justify the Hype?
Shares of 10x Genomics surged 10.3% to $57.39 on Monday, extending a post-earnings rally that has lifted the stock roughly 22% in three trading sessions. The...
🟢 10x Genomics is trading 10% up today after Canaccord raised its price target to $60
10x Genomics is trading at $57.39 (+10.30%) after Canaccord raised its price target to $60 from $50 and Piper Sandler lifted its target to $47 from $42. - The...
🟢 10x Genomics is trading 5% up today after raising full-year 2026 guidance
10x Genomics is trading at $54.80 (+5.32%) as it extends its August 7, 2026 post-earnings rally after raising full-year 2026 guidance. - Second-quarter...
🟢 10x Genomics is trading 5% up today after raising 2026 revenue guidance
10x Genomics is trading 5.16% up now at $47.89 after its August 6 earnings beat revenue expectations and management raised full-year 2026 revenue guidance. -...
🔴 10x Genomics is trading 4.93% down in pre-market after investors focused on Atera transition
10x Genomics is trading at $43.35 (-4.93%) after August 6, 2026 release triggered a negative after-hours reaction despite revenue and adjusted-loss beats;...
🔴 10x Genomics is trading 4.7% down today in after-hours trading after rising expenses
10x Genomics is trading 4.7% down at $43.45 in after-hours trading after investors may be emphasizing slower reported growth and higher expenses despite raised...
10x Genomics' second quarter 2026 revenue of $151M beat estimates while narrowing its net loss
10x Genomics reported second quarter 2026 revenue of $151.0 million, exceeding analyst estimates of $146.67 million. While reported revenue declined...
🔴 10x Genomics is trading 4.5% down today ahead of Q2 2026 results
10x Genomics is trading 4.5% down at $45.32, with pre-earnings positioning and valuation concerns the most likely immediate pressures ahead of its Q2 2026...
10x Genomics, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect 10x Genomics to report Q2 2026 revenue of $146.67 million and a consensus EPS loss of $0.23, with the stock’s current price of $47.27 trading...
🟢 10x Genomics is trading 4.1% up today as risk sentiment improves after sector-led pullback
10x Genomics is trading at $49.20 (4.1%) up in pre-market as the stock rebounds from a recent biotech-led pullback. • The move appears driven by firmer index...
🔴 10x Genomics is trading 4.3% down today amid a broader biotech pullback
10x Genomics is trading 4.3% down today at $47.29 amid a broader pullback in biotechnology stocks and a shift in market sentiment. • The move gives back a...
🟢 10x Genomics is trading 4% up today amid a tech-led rally and cooling inflation data
10x Genomics is trading 4% up today at $48.18 as risk-on sentiment returns to growth and technology names. • The broader market is rallying, with the Nasdaq...
🔴 10x Genomics is trading 4.1% down today amid profit-taking after recent gains
10x Genomics is trading 4.1% down at $46.08 as investors lock in profits following a period of significant upward momentum. • The stock recently experienced a...
🔴 10x Genomics is trading 4.7% down today amid broader biotech weakness and profit-taking
10x Genomics is trading at $43.61 (-4.68%) following a sharp pullback in early trading, moving lower alongside broader weakness in the biotech and technology...
🟢 10x Genomics is trading 4% up today following a significant analyst upgrade
• 10x Genomics is trading at approximately $43.45 (4% up) today. • Canaccord Genuity Group increased its price target for TXG from $32.00 to $50.00 and...
10x Genomics Surges Past $42 on Proteintech Deal Euphoria — But Can an Unprofitable Company Justify This Rally?
Shares of 10x Genomics (TXG) jumped 12.9% to $42.32 on July 9, blowing past a 52-week high the stock had only just set days earlier, as investors continue to...
🟢 10x Genomics is trading 11.7% up today on Proteintech Genomics acquisition optimism
10x Genomics is trading 11.7% up now at $42.32 as investors continue to react positively to the strategic benefits of its Proteintech Genomics acquisition. •...
🟢 TXG is trading 2.2% up today, extending multi-session gains on recent acquisition, collaboration, and analyst rating
TXG is trading at $37.96 (+2.19%), continuing a strong multi-session recovery fueled by recent positive developments: * The company announced the...
🟢 TXG is trading 3.6% up today, extending rally after Barclays price target hike
TXG is trading at $37.00 (3.6% up), extending a strong multi-day rally following a Barclays price target increase to $40 and a reaffirmed Overweight rating. •...